VLDL triglycerides inhibit HDL-associated paraoxonase 1 (PON1) activity: In vitro and in vivo studies

BioFactors

Volumn 38, Issue 4, 2012, Pages 292-299

  Rosenblat, Mira ^a   Ward, Sarah ^a   Volkova, Nina ^a   Hayek, Tony ^a   Aviram, Michael ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Bezafibrate; HDL; Hypertriglyceridemic patients; Paraoxonase 1 (PON1); Triglyceride; VLDL

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; BEZAFIBRATE; GLUCONOLACTONASE; LIPID EMULSION; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CASE REPORT; CHOLESTEROL TRANSPORT; DRUG EFFECT; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HUMAN; HYPERTRIGLYCERIDEMIA; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANIMALS; ARYLDIALKYLPHOSPHATASE; BEZAFIBRATE; CASE-CONTROL STUDIES; CELL LINE; CHOLESTEROL; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; MACROPHAGES; MICE; MIDDLE AGED; TRIGLYCERIDES; TRIOLEIN;

EID: 84865144449     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1021     Document Type: Article

References (34)

1. Goldberg, I. J., Eckel, R. H., McPherson, R. ( 2011) Triglyceride and heart disease. Still a hypothesis? Arterioscler. Thromb. Vasc. Biol. 31, 1716-1725.
2. Carmena, R., Duriez, P., Fruchart, J. C. ( 2004) Atherogenic lipoprotein particles in atherosclerosis. Circulation. 109, III2-III7.
3. Cullen, P. ( 2000) Evidence that triglycerides are an independent coronary heart disease risk factor. Am. J. Cardiol. 86, 943-949.
4. Sarwar, N., Sandhu, M. S., Ricketts, S. L., Butterworth, A. S., Di Angelantonio, E., Boekholdt, S. M., Ouwehand, W., Watkins, H., Samani, N. J., Saleheen, D., Lawlor, D., Reilly, M. P., Hingorani, A. D., Talmud, P. J., Danesh, J.( 2010) Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Lancet. 375, 1634-1639.
5. Nordestgaard, B. G., Benn, M., Schnohr, P., Tybjaerg-Hansen, A. ( 2007) Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 298, 299-308.
6. Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., Strait, J., Duren, W. L., Maschio, A., Busonero, F., Mulas, A., Albai, G., Swift, A. J., Morken, M. A., Narisu, N., Bennett, D., Parish, S., Shen, H., Galan, P., Meneton, P., Hercberg, S., Zelenika, D., Chen, W. M., Li, Y., Scott, L. J., Scheet, P. A., Sundvall, J., Watanabe, R. M., Nagaraja, R., Ebrahim, S., Lawlor, D. A., Ben-Shlomo, Y., Davey-Smith, G., Shuldiner, A. R., Collins, R., Bergman, R. N., Uda, M., Tuomilehto, J., Cao, A., Collins, F. S., Lakatta, E., Lathrop, G. M., Boehnke, M., Schlessinger, D., Mohlke, K. L., Abecasis, G. R.( 2008) Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 40, 161-169.
7. Lang, P. D., Insull, W., Jr. ( 1970) Lipid droplets in atherosclerotic fatty streaks of human aorta. J. Clin. Invest. 49, 1479-1488.
8. Mattsson, L., Johansson, H., Ottosson, M., Bondjers, G., Wiklund, O.( 1993) Expression of lipoprotein lipase mRNA and secretion in macrophages isolated from human atherosclerotic aorta. J. Clin. Invest. 92, 1759-1765.
9. Keating, G. M., Ormrod, D. ( 2002) Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs. 62, 1909-1944.
10. Milosavljevic, D., Griglio, S., Le Naour, G., Chapman, M. J. ( 2001) Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages. Atherosclerosis 155, 251-260.
11. Draganov, D. I., Teiber, J. F., Speelman, A., Osawa, Y., Sunahara, R., La Du, B. N.( 2005) Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid. Res. 46, 1239-1247.
12. Gaidukov, L., Tawfik, D. S. ( 2005) High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 44, 11843-11854.
13. Rosenblat, M., Aviram, M. ( 2009) Paraoxonases role in the prevention of cardiovascular diseases. Biofactors 35, 98-104.
14. Efrat, M., Aviram, M. ( 2008) Macrophage paraoxonase 1 (PON1) binding sites. Biochem. Biophys. Res. Commun. 376, 105-110.
15. Rozenberg, O.; Shih, D. M., Aviram, M. ( 2005) Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 18, 19-18.
16. Rozenberg, O., Shih, D. M., Aviram, M. ( 2003) Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation, Arterioscler. Thromb. Vasc. Biol. 23, 461-467.
17. Rosenblat, M., Gaidukov, L., Khersonsky, O., Vaya, J., Oren, R., Tawfik, D. S., Aviram, M.( 2006) The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J. Biol. Chem. 281, 7657-7665.
18. Brites, F. D., Verona, J.; Schreier, L. E., Fruchart, J. C., Castro, G. R., Wikinski, R. L.( 2004) Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia. Arch. Med. Res. 35, 235-240.
19. Samy, W., Hassanian, M. A. ( 2011) Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin. Arab. J. Gastroenterol. 12, 80-85.
20. Beer, S., Moren, X., Ruiz, J., James, R. W.( 2006) Postprandial modulation of serum paraoxonase activity and concentration in diabetic and non-diabetic subjects. Nutr. Metab. Cardiovasc. Dis. 16, 457-465.
21. Fuhrman, B., Volkova, N., Aviram, M. ( 2006) Postprandial serum triacylglycerols and oxidative stress in mice after consumption of fish oil, soy oil or olive oil: possible role for paraoxonase-1 triacylglycerol lipase-like activity. Nutrition. 22, 922-930.
22. Aharoni, A., Gaidukov, L., Yagur, S., Toker, L., Silman, I., Tawfik, D. S.( 2004) Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc. Natl. Acad. Sci. U S A 101, 482-487.
23. Aviram, M. ( 1983) Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients. Biochem. Med. 30, 111-118.
24. Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, R. J.( 1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275.
25. 3H] cholesterol efflux to high and low density lipoproteins is dependent on lipoprotein binding to the receptor. J. Biol. Chem. 275, 29939-30001.
26. Tavori, H., Khatib, S., Aviram, M., Vaya, J. ( 2008) Characterization of the PON1 active site using modeling simulation, in relation to PON1 lactonase activity. Bioorg. Med. Chem. 16, 7504-7509.
27. Salman, M., Malleda, C., Suneel, N. A., Qureshi, I. A., Frank, E. A., D'Souza, C. J.( 2011) Homology modeling of human serum paraoxonase1 and its molecular interaction studies with aspirin and cefazolin. Bioinformation 7, 59-63.
28. Staels, B., Dallongeville, J., Auwerx, J., et al. ( 1998) Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98, 2088-2093.
29. Paragh, G., Seres, I., Harangi, M., Erdei, A., Audikovszky, M., Debreczeni, L., Kovácsay, A., Illyés, L., Pados, G.( 2006) Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome. Br. J. Clin. Pharmacol. 61, 694-701.
30. Balogh, Z., Seres, I., Harangi, M., Kovács P, Kakuk G, Paragh G.( 2001) Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates? Diabetes Metab. 27, 604-610.
31. Phuntuwate, W., Suthisisang, C., Koanantakul, B., Chaloeiphap, P., Mackness, B., Mackness, M.( 2008) Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels. Atherosclerosis 196, 122-128.
32. Dullaart, R. P., de Vries, R., Voorbij, H. A., Sluiter, W. J., van Tol, A.( 2009) Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus. Eur. J. Clin. Invest. 39, 200-203.
33. Durrington, P. N., Mackness, M. I., Bhatnagar, D., Julier, K., Prais, H., Arrol, S., Morgan, J., Wood, G. N.( 1998) Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis 138, 217-225.
34. Gouédard, C., Koum-Besson, N., Barouki, R., Morel, Y.( 2003) Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol. Pharmacol. 63, 945-956.